Commentary :
Group members of [NCER-PD Consortium]
Geeta Acharya2, Gloria Aguayo2, Myriam Alexandre2, Muhammad Ali1, Wim Ammerlann2, Giuseppe Arena1, Rudi Balling1, Michele Bassis1, Roxane Batutu3, Katy Beaumont2, Regina Becker1, Camille Bellora2, Guy Berchem3, Daniela Berg11, Alexandre Bisdorff5, Ibrahim Boussaad1, Kathrin Brockmann11, Jessica Calmes2, Lorieza Castillo2, Gessica Contesotto2, Nancy De Bremaeker3, Nico Diederich3, Rene Dondelinger5, Daniela Esteves2, Guy Fagherazzi2, Jean-Yves Ferrand2, Manon Gantenbein2, Thomas Gasser11, Piotr Gawron1, Soumyabrata Ghosh1, Marijus Giraitis2,3, Enrico Glaab1, Elisa Gómez De Lope1, Jérôme Graas2, Mariella Graziano17, Valentin Groues1, Anne Grünewald1, Wei Gu1, Gaël Hammot2, Anne-Marie Hanff2,20,21, Linda Hansen1,3, Michael Heneka1, Estelle Henry2, Sylvia Herbrink6, Sascha Herzinger1, Michael Heymann2, Michele Hu8, Alexander Hundt2, Nadine Jacoby18, Jacek Jaroslaw Lebioda1, Yohan Jarosz1, Sonja Jónsdóttir2, Quentin Klopfenstein1, Jochen Klucken1,2,3, Rejko Krüger1,2,3, Pauline Lambert2, Zied Landoulsi1, Roseline Lentz7, Inga Liepelt11, Robert Liszka14, Laura Longhino3, Victoria Lorentz2, Paula Cristina Lupu2, Tainá M. Marques1, Clare Mackay10, Walter Maetzler15, Katrin Marcus13, Guilherme Marques2, Patricia Martins Conde1, Patrick May1, Deborah Mcintyre2, Chouaib Mediouni2, Francoise Meisch1, Myriam Menster2, Maura Minelli2, Michel Mittelbronn1,4, Brit Mollenhauer12, Friedrich Mühlschlegel4, Romain Nati3, Ulf Nehrbass2, Sarah Nickels1, Beatrice Nicolai3, Jean-Paul Nicolay19, Fozia Noor2, Marek Ostaszewski1, Clarissa P. C. Gomes1, Sinthuja Pachchek1, Claire Pauly1,3, Laure Pauly2, 20, Lukas Pavelka1,2,3, Magali Perquin2, Nancy E. Ramia1, Rosalina Ramos Lima2, Armin Rauschenberger1, Rajesh Rawal1, Dheeraj Reddy Bobbili1, Kirsten Roomp1, Eduardo Rosales2, Isabel Rosety1, Estelle Sandt2, Stefano Sapienza1, Venkata Satagopam1, Margaux Schmitt2, Sabine Schmitz1, Reinhard Schneider1, Jens Schwamborn1, Amir Sharify2, Ekaterina Soboleva1, Kate Sokolowska2, Hermann Thien2, Elodie Thiry1,3, Rebecca Ting Jiin Loo1, Christophe Trefois1, Johanna Trouet2, Olena Tsurkalenko2, Michel Vaillant2, Mesele Valenti2, Gilles Van Cutsem1,3, Carlos Vega1, Liliana Vilas Boas3, Maharshi Vyas1, Richard Wade-Martins9, Paul Wilmes1, Evi Wollscheid-Lengeling1, Gelani Zelimkhano3.
1Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
2Luxembourg Institute of Health, Strassen, Luxembourg.
3Centre Hospitalier de Luxembourg, Strassen, Luxembourg.
4Laboratoire National de Santé, Dudelange, Luxembourg.
5Centre Hospitalier Emile Mayrisch, Esch-sur-Alzette, Luxembourg.
6Centre Hospitalier du Nord, Ettelbrück, Luxembourg.
7Parkinson Luxembourg Association, Leudelange, Luxembourg.
8Oxford Parkinson’s Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
9Oxford Parkinson’s Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, United Kingdom.
10Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
11Center of Neurology and Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University Hospital Tübingen, Germany.
12Paracelsus-Elena-Klinik, Kassel, Germany.
13 Ruhr-University of Bochum, Bochum, Germany.
14Westpfalz-Klinikum GmbH, Kaiserslautern, Germany.
15Department of Neurology, University Medical Center Schleswig-Holstein, Kiel, Germany.
16Department of Neurology Philipps, University Marburg, Marburg, Germany.
17Association of Physiotherapists in Parkinson’s Disease Europe, Esch-sur-Alzette, Luxembourg.
18Private Practice, Ettelbruck, Luxembourg.
19 Private Practice, Luxembourg, Luxembourg.
20Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
21Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre+, Maastricht, Netherlands.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the Luxembourg National Research Fund (FNR) within the National Centre of Excellence in Research in Parkinson’s disease [NCER- PD; (FNR/NCER13/BM/11264123)] and the PEARL programme (FNR; FNR/P13/6682797 to RK) as well as by the European Union’s Horizon 2020 research and innovation program under Grant Agreement No. 692320 (WIDESPREAD; CENTRE-PD; Grant Agreement No. 692320; CENTRE-PD to RK); dHealthPD PEARL programme to JK (14146272); DIGIPD (ERAPERMED 2020-314) to EG, RECAST (INTER/22/17104370) to EG.
Acknowledgments
We would like to give special thanks to all the study participants. Additionally, we are very grateful for all the funding and private donations that enabled us to carry out the project. Furthermore, we acknowledge the joint effort of the NCER-PD consortium members generally contributing to the Luxembourg Parkinson’s study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
